丹麦明星减肥药厂Zealand发布成绩单 新药实现16周减重8.6%

丹麦明星减肥药厂Zealand发布成绩单 新药实现16周减重8.6%

  本地时候周四,丹麦生物手艺公司Zealand制药发布通知布告称,公司在研的长效胰淀素(amylin)近似物petrelintide在Ⅰb期实验中获得积极的顶线成果。  Zealand制药指出,今朝的一系列临床数据和研究都显示,相较于GLP-1药物,petrelintide有潜力供给不异的减重结果,同时耐受性更好,从而供给更好的减肥体验。从Zealand制药发布的实验成果来看,在1b实验阶段有48名介入者(8成男性),春秋中位数为49岁,BMI中位数为29。  在为期16周的尝试中,每周打针一次petrelintide。成果显示,高剂量组的受试者在16周里平均体重从基线降落8.6%,作为对照的抚慰剂组仅降落了1.7%。

发布于:
意见反馈 合作

Copyright © 2024 WKMCAWTUA Sohu All Rights Reserved

霸百科技 版权所有

 Koss公司 (纳斯达克: KOSS) 的股票可能已经下跌了27%,但便宜买入仍然不太可能。

Koss公司 (纳斯达克: KOSS) 的股票可能已经下跌了27%,但便宜买入仍然不太可能。

Koss公司 (纳斯达克: KOSS) 的股票可能已经下跌了27%,但便宜买入仍然不太可能。

The Koss Corporation (NASDAQ:KOSS) share price has softened a substantial 27% over the previous 30 days, handing back much of the gains the stock has made lately. Indeed, the recent drop has reduced its annual gain to a relatively sedate 4.3% over the last twelve months. Even after such a large drop in price, you could still be forgiven for thinking Koss is a stock to steer clear of with a price-to-sales ratios (or "P/S") of 2.9x, considering almost half the companies in the United States' Consumer Durables industry have P/S ratios below 0.8x. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified. NasdaqCM:KOSS Price to Sales Ratio vs Industry June 20th 2024 What Does Koss' Recent Performance Look Like? For example, consider that Koss' financial performance has been poor lately as its revenue has been in decline. One possibility is that the P/S is high because investors think the company will still do enough to outperform the broader industry in the near future. However, if this isn't the case, investors might get caught out paying too much for the stock. We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Koss' earnings, revenue and cash flow. How Is Koss' Revenue Growth Trending? The only time you'd be truly comfortable seeing a P/S as steep as Koss' is when the company's growth is on track to outshine the industry decidedly. Retrospectively, the last year delivered a frustrating 13% decrease to the company's top line. The last three years don't look nice either as the company has shrunk revenue by 31% in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company. Weighing that medium-term revenue trajectory against the broader industry's one-year forecast for expansion of 4.5% shows it's an unpleasant look. With this information, we find it concerning that Koss is trading at a P/S higher than the industry. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. There's a very good chance existing shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the recent negative growth rates. The Key Takeaway Even after such a strong price drop, Koss' P/S still exceeds the industry median significantly. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company. Our examination of Koss revealed its shrinking revenue over the medium-term isn't resulting in a P/S as low as we expected, given the industry is set to grow. Right now we aren't comfortable with the high P/S as this revenue performance is highly unlikely to support such positive sentiment for long. Unless the recent medium-term conditions improve markedly, investors will have a hard time accepting the share price as fair value. It's always necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Koss (at least 1 which is potentially serious), and understanding them should be part of your investment process. If you're unsure about the strength of Koss' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

发布于:
意见反馈 合作

Copyright © 2024 WKMCAWTUA Sohu All Rights Reserved

霸百科技 版权所有

404页面